Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

EPN-701 (Oral)

Phase 2Small molecule

EEpizon Pharma, Inc.

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

CalciphylaxisNot yet recruiting

CalciphylaxisPhase 2

Not yet recruiting

Timeline

Expected Milestones

Q2 2030

Phase 2Not yet recruiting

Calciphylaxis

NCT07583745

Clinical

Trials by Indication[1]

End Stage Renal Disease (ESRD)1 trial

A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)

Completed·EEpizon Pharma, Inc.·Phase 2·NCT05285787·18 enrolled

Calciphylaxis1 trial

Phase 2 Study of EPN-701 for the Treatment of Calciphylaxis

Not yet recruiting·SSagar U. Nigwekar, MD, MMSc·Phase 2·NCT07583745·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for EPN-701 (Oral). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EPN-701 (Oral) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EPN-701 (Oral). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Epizon Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEpizon Pharma, Inc.

Related News